Gomez-Centeno, Antonio http://orcid.org/0000-0002-8674-6692
Rubio-Romero, Esteban
Ovalles, Juan Gabriel http://orcid.org/0000-0001-6300-5341
Manrique-Arija, Sara http://orcid.org/0000-0003-2284-7846
Marsal-Barril, Sara http://orcid.org/0000-0001-5515-3854
Amarelo-Ramos, Juan
del Pino-Montes, Javier http://orcid.org/0000-0002-3145-6137
Muñoz-Fernández, Santiago
Bustabad, Sagrario
Barbazán-Álvarez, Ceferino
Funding for this research was provided by:
This study was supported by Sanofi Genzyme Spain
Article History
Received: 7 May 2019
Accepted: 9 July 2019
First Online: 8 August 2019
Compliance with ethical standards
:
: Dr Rubio reports speaker contributions for Lilly, Pfizer, Abbvie, Novartis, MSD, Celltrion, Sanofi, Roche, Gebro, Nordic, Grunenthal and UCB and was an advisor for Lilly, Sanofi, Biogen and Novartis. Dr Gómez-Centeno reportsspeaking fees from Pfizer, Lilly, Rubió, Abbvie, Sanofi, Roche, Janssen, travel expenses covered from Pfizer, Abbvie, Lilly, and was an advisor for Pfizer, Abbvie,Lilly, Sanofi, Rubió, Sandoz, Biogen and Gilead. Dr Gabriel Ovalles reports consultation and speaking fees from Abbvie, BMS, Celgene, Janssen, MSD, Novartis, Pfizer, Roche, Sanofi and UCB Pharma. Dr Manrique Arija reports speaking fees from Pfizer, Abbvie, MSD, UCB, Lilly, Novartis and Roche. Dr Marsal Barril was an advisor for Pfizer, Celgene, MSD, BMS, Abbvie, Sandoz, Novartis, Roche, UCB, Lilly, Sanofi and Janssen. Dr Amarelo Ramos reports speaking fees and consultancy from Sanofi and was an advisor for Novartis. Dr del Pino Montes reports consultancy from Amgen, Lilly, Pfizer, MSD, Abbvie, BMS, Novartis, Janssen and Sanofi. Dr Muñoz-Fernández reports speaking fees or was an advisor for MSD, Pfizer, Abbvie, Novartis, Janssen, UCB, Sanofi, Roche, Celgene and Gebro. Dr Bustabad was an advisor for Pfizer, AbbVie, Novartis, Sanofi, Roche, UCB and Janssen. Dr Barbazán Álvarez reports consultancy and expert testimony for Sanofi, Celgene, Novartis, Pfizer, Abbvie, Lilly, a grant from Janssen, speaker fees from Celgene, Sanofi, Novartis, Pfizer, Abbvie, Lilly and Roche, travel expenses covered from MSD, Abbvie, Lilly, Sanofi and Pfizer.
: The Ethics Committee of Hospital Parc Taulí, Sabadell, approved the study protocol (study code DIREGL08326) and allowed the retrospective analysis of available records of the patients between 2013 and 2016. The study was conducted in accordance with the principles of the Declaration of Helsinki of 1975/83.
: Informed consent was obtained from all individual participants included in the study.